Presentation is loading. Please wait.

Presentation is loading. Please wait.

SDC 3: Time until virologic suppression and failure

Published bySudomo Susanto Modified over 5 years ago

Similar presentations

Presentation on theme: "SDC 3: Time until virologic suppression and failure"— Presentation transcript:

1 SDC 3: Time until virologic suppression and failure
Duration until subsequent virological failure Duration until first virological suppression N: %: N: %: ART: antiretroviral therapy; N: number of children; %: proportion of children

Download ppt "SDC 3: Time until virologic suppression and failure"

Similar presentations

Paediatric Language Group

Paediatric Language Group
European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.

European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
Children Aged 5 to

Children Aged 5 to
HIV antibody detection in children who started antiretroviral treatment in infancy Louise Kuhn, Diana Schramm, Stephanie Shiau, Renate Strehlau, Maria.

HIV antibody detection in children who started antiretroviral treatment in infancy Louise Kuhn, Diana Schramm, Stephanie Shiau, Renate Strehlau, Maria.
Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Www.aidsdatahub.org HIV and AIDS Data Hub for Asia-Pacific Review in slides Children Last updated: February 2015.

HIV and AIDS Data Hub for Asia-Pacific Review in slides Children Last updated: February 2015.
Www.guscairns.com BHIVA 2006 Gus Cairns. www.guscairns.com BHIVA 2006 – selected studies People with CD4s

BHIVA 2006 Gus Cairns. BHIVA 2006 – selected studies People with CD4s
Www.aidsdatahub.org HIV and AIDS Data Hub for Asia-Pacific Review in slides Treatment Last updated: December 2014.

HIV and AIDS Data Hub for Asia-Pacific Review in slides Treatment Last updated: December 2014.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*

Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.

The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.
The Role of Maraviroc in Antiretroviral Therapy for Treatment-Experienced Patients Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and.

The Role of Maraviroc in Antiretroviral Therapy for Treatment-Experienced Patients Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.

Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.

The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
02-15 INFC-1022464-0001 Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:

02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:

Similar presentations

Ads by Google